Foghorn Therapeutics Inc.
FHTX
View Detailed Chart
5.680USD
+0.450+8.60%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
321.16MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+8.60%
5 Days
-0.53%
1 Month
+15.21%
6 Months
+15.92%
Year to Date
+5.19%
1 Year
+37.86%
View Detailed Chart
TradingKey Stock Score of Foghorn Therapeutics Inc.
Currency: USD Updated: 2026-02-06Key Insights
Foghorn Therapeutics Inc.'s fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 71 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 11.33.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Foghorn Therapeutics Inc.'s Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Foghorn Therapeutics Inc. Highlights
StrengthsRisks
Foghorn Therapeutics Inc. is a clinical-stage, precision therapeutics biotechnology company. The Company is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 17.55% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 22.60M.
Undervalued
The company’s latest PE is -5.03, at a low 3-year percentile range.
Held by Invesco
Star Investor Invesco holds 3.15K shares of this stock.
Analyst Rating
Based on
10
analysts
Strong Buy
Current Rating
11.333
Target Price
+116.70%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Foghorn Therapeutics Inc. News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Foghorn Therapeutics Inc. Info
Foghorn Therapeutics Inc. is a clinical-stage, precision therapeutics biotechnology company. The Company is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.
Ticker SymbolFHTX
CompanyFoghorn Therapeutics Inc.
CEOGottschalk (Adrian)
Websitehttps://foghorntx.com/
Related Instruments
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69910.880
-59.250 (-0.08%)
282.580
+22.390 (+8.61%)
2073.180
+21.450 (+1.04%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
